全球最大！上交所受理

Core Viewpoint - The IPO application of Ningbo Jianxin Superconducting Technology Co., Ltd. has been accepted, marking it as the third company to receive approval for an IPO on the Sci-Tech Innovation Board this year, highlighting the ongoing effects of the "Sci-Tech Innovation Board Eight Articles" policy [1] Company Overview - Jianxin Superconducting is the largest independent supplier of superconducting magnets globally, breaking the monopoly of international giants in the core components of MRI [1][2] - The company aims to raise 865 million yuan through its IPO to seize industry development opportunities [1] Market Position and Competition - Jianxin Superconducting's main products, including superconducting magnets, permanent magnets, and gradient coils, account for approximately 50% of the cost of MRI equipment [3] - The MRI core component market has been dominated by international giants like GE Healthcare, Siemens Healthineers, and Philips Healthcare, which hold over 80% of the global market share [3] - Jianxin Superconducting has closed the technological gap with international competitors by about 20 years in the mainstream zero-evaporation superconducting magnet field and has transitioned from a follower to a leader in the liquid helium-free superconducting magnet sector [4] Financial Performance - The company's revenue for 2022, 2023, and 2024 is reported as 359 million yuan, 451 million yuan, and 425 million yuan respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [4][5] Industry Growth and Opportunities - The global MRI equipment market is in a phase of technological upgrade and market expansion, with a projected growth from 11.1 billion USD in 2024 to 14.89 billion USD by 2030, reflecting a compound annual growth rate of approximately 5.0% [7] - The Chinese market is identified as the largest incremental market, with policies encouraging the procurement of domestic high-end medical equipment and increased financial subsidies for medical device R&D [9] IPO Fund Utilization - The funds raised from the IPO will be directed towards projects including the annual production of 600 sets of liquid helium-free superconducting magnets, technological upgrades for high-field medical superconducting magnets, and new superconducting magnet R&D [9][11] - The successful implementation of these projects is expected to enhance the production capacity of high-end products and solidify the company's leading position in the liquid helium-free technology sector [11]